Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building,
CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago,
UC = Conference Chicago at University Center
* = applied session ! = JSM meeting theme
Activity Details
254 * !
Mon, 8/1/2016,
2:00 PM -
3:50 PM
CC-W192c
Early-Phase Clinical Trials: Setting the Stage for Success — Contributed Papers
Biopharmaceutical Section
Chair(s): Yanxun Xu
2:05 PM
Randomization does not prevent bias when we assess treatment by covariate interaction
—
Lei Nie, FDA ; Zhiwei Zhang, FDA/CDRH ; Jialu Zhang, FDA
2:20 PM
Application of Propensity-Score Matching in Data Augmentation of Randomized Clinical Trials: A Case Study
—
Junjing Lin, AbbVie ; Margaret Gamalo-Siebers, Eli Lilly and Company ; Ram Tiwari, FDA/CDER/OT/OB
2:35 PM
Enabling Robust PK/QTc Assessment in Single and Multiple Ascending Dose Trials for Evaluation of QTc Prolongation
—
Fang Liu, Merck ; Li Fan, Merck ; Kuenhi Tsai, Merck ; Devan V. Mehrotra, Merck
2:50 PM
Enrichment Design with Patient Augmentation for Time-to-Event Data
—
Yijie Zhou, AbbVie ; Bo Yang, Vertex Pharmaceuticals ; Lanju Zhang, AbbVie ; Lu Cui, AbbVie
3:05 PM
Dose-Ranging Design and Analysis Based on MCP-Mod to Identify the Minimum Effective Dose (MED)
—
Ying Zhang, AbbVie ; Su Chen, AbbVie ; Yihan Li, AbbVie ; Wangang Xie, AbbVie ; Yijie Zhou, AbbVie ; Li Wang, AbbVie ; Alan Hartford, AbbVie
3:20 PM
Optimal Borrowing of Historical Control Data in Clinical Trials
—
Saurabh Mukhopadhyay, AbbVie ; Qi Tang, AbbVie ; Alan Hartford, AbbVie
3:35 PM
Never Fit Sequence: The Design and Analysis of Multi-Period Clinical Trials
—
Hans Hockey, Biometrics Matters Ltd.
